FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an improved commercial method for preparing officinal diosmin of raw diosmin in the form of a crystalline form of diosmin monohydrate, which consists in removing of foreign substances by dissolving of raw diosmin in anhydrous aliphatic alcoholin the presence of alkaline metal alkoxide or hydroxide, deposition of thee diosmin crystals from condensed alcohol solution at pH 4÷5,5, drying in vacuum at 40÷60°C and grinding of the crystals to prepare light-yellow diosmin monohydrate of purity more than 97%, particle size ≤ 4 mcm, and extra drying at more than 110°C to prepare the crystalline form of anhydrous diosmin. There are shown a powder X-ray diffraction pattern and a thermo-gravimetric differential thermal image of the crystalline forms of diosmin which provide a basis to set their crystalline structure.
EFFECT: developing the improved commercial method for preparing officinal diosmin of raw diosmin in the form of the crystalline diosmin monohydrate.
27 cl, 5 ex, 8 tbl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FORM IV OF TILORONE DIHYDROCHLORIDE, AND INDUSTRIAL METHOD FOR ITS PRODUCTION (VERSIONS) | 2012 |
|
RU2509074C2 |
| NOVEL CRYSTALLINE FORMS OF SODIUM SALT OF (4-{4-[5-(6-TRIFLUOROMETHYL-PYRIDIN-3-YLAMINO)PYRIDIN-2-YL]PHENYL}CYCLOHEXYL) ACETIC ACID | 2011 |
|
RU2612556C2 |
| NEW CRYSTALLINE FORMS OF TIOTROPIUM BROMIDE | 2006 |
|
RU2417224C2 |
| HEMIHYDRATE OF NALTREXONE BASE, METHOD FOR ITS OBTAINING AND METHOD FOR MICROSPHERES MANUFACTURING | 2012 |
|
RU2505542C1 |
| CRYSTALLINE FORM II OF TILORONE AND METHOD OF OBTAINING THEREOF (VERSIONS) | 2011 |
|
RU2521595C2 |
| POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND | 2010 |
|
RU2575173C2 |
| BILASTIN CRYSTALLINE FORMS AND THEIR PRODUCTION METHODS | 2016 |
|
RU2772222C2 |
| CRYSTALLINE POLYMORPHS MONOHYDRATES OF 8-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-5N-DIBENZO[B,E][1,4]DIAZEPINE (CLOZAPINE) | 2018 |
|
RU2715717C1 |
| NOVEL SOLID FORMS (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | 2020 |
|
RU2820501C2 |
| NEW CRYSTALLINE SALT FORM OF 2,2-DIMETHYL-6-((4-((3,4,5-TRIMETHOXYPHENYL)AMINO)-1,3,5-TRIAZIN-2-YL)AMINO)-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE FOR MEDICAL USE | 2016 |
|
RU2621187C1 |
